Barclays raised the firm’s price target on Crispr Therapeutics (CRSP) to $12 from $10 and keeps an Overweight rating on the shares post the Q2 report. The company beat estimates on better margins and double-digit Components and Systems growth, the analyst tells investors in a research note. The firm says market adoption of Crispr’s new products has been positive.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRSP:
- Cathie Wood ‘Buys the Dip’ in AMD Stock after Q2 Results, Cuts Roblox and Palantir (PLTR) Stakes
- Crispr Therapeutics AG: Strong Sales Growth and Global Expansion Justify Buy Rating
- CRSP, TWST: Cathie Wood Bets Millions on Biotech, Continues Dumping Roblox
- Crispr Therapeutics’ CTX112 Study: A Promising Step in Autoimmune Disease Treatment
- Cathie Wood’s ARK Investment buys 181.3K shares of Crispr Therapeutics today